Abstract Despite significant medical advances, glioblastoma multiforme (GBM) remains a formidable therapeutic challenge. Advent of targeted capture sequencing and patients-derived organoid cultures may hold the key to scientifically sound individualized treatment approaches. We report on our initial experience of using the combination of these two technologies to create a […]
Patient-derived tumor organoid predicts drugs response in glioblastoma: A step forward in personalized cancer therapy?
